PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer

NCT05033392 | Recruiting Phase 2

• 1 other identifier: PNACGEC
• Study Type: interventional
• Target: 62
• Locations: 1 country
• Sites: 2

Brief Summary

Gastric cancer (GC),including cardia and noncardia gastric cancer, is responsible for over 480,000 new cases in 2020 and an estimated 370,000 deaths, making it the third most frequently diagnosed cancer and the third leading cause of cancer death in China. Majority of patients(63%) are presented with locally advanced gastric cancer (stage Ⅱ/Ⅲ) and the prognosis is poor. Previous studies have shown that patients with pathological complete response(pCR) following neoadjuvant therapy have longer survival. In 2019, Lancet Oncology published the FLOT4-AIO study which testified that perioperative chemotherapy with FLOT (5-FU/LV, oxaliplatin and docetaxel) regimen has improved pCR rate and prolonged progression free survival(PFS) and overall survival(OS) in patients with stage II/III gastric cancer. Moreover, PD-1 blockade such as nivolumab or pembrolizumab in combination with chemotherapy has shown higher objective response rate(ORR) as compared to chemotherapy alone in advanced gastric cancer. The nanoparticle albumin-bound paclitaxel has been recommended as the second-line chemotherapy for unresectable or recurrent gastric cancer based on the Chinese Society of Clinical Oncology(CSCO) guideline. When PD-1 antibody is applied, albumin-bound paclitaxel is considered as a better partner since no pretreatment of corticosteroids is needed. Thus, the investigators plan to conduct a phase II clinical trial to evaluate the efficacy and safety of toripalimab (PD-1 antibody) combined with the FLOAP (albumin-bound paclitaxel, oxaliplatin, fluorouracil and leucovorin) regimen as the perioperative treatment of cT2-4 and/or N+ GC. The primary end point is pCR rate. The secondary end points include disease free survival(DFS), OS, ORR, R0 resection rate, incidence of adverse events(AE).

Conditions

Stomach Neoplasms

Keywords

PD-1 antibody; neoadjuvant chemotherapy; gastric cancer; gastroesophageal junction cancer

Outcome Measures

Primary Outcomes (1)

• Pathological complete response rate

  The proportion of patients with no tumor cells in the postoperative specimens

  Up to 6 months

Secondary Outcomes (5)

• Disease Free Survival

  Up to 5 years

• Overall Survival

  Up to 5 years

• Objective Response Rate

  Up to 6 months

• R0 Resection Rate

  Up to 6 months

• Incidence of Adverse Events

  Up to 6 months

Study Arms (1)

Toripalimab group

EXPERIMENTAL

Toripalimab is administrated with160mg and repeated every 2 weeks.

Drug: Toripalimab Injection

Interventions

Toripalimab Injection DRUG

A domestic PD-1 antibody

Also known as: JS001

Toripalimab group

Eligibility Criteria

• Age: 18 Years - 79 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 yeas and ≤79 years. The gender is not limited.
• Confirmed gastric and gastroesophageal junction adenocarcinoma by Gastroscopic biopsy histopathological examination.
• Endoscopic ultrasonography and/or enhanced CT/MRI examination confirmed at the stage of cT3/4a Nx or T2 N1-3, M0(AJCC 8th) before randomization.
• At least 15 unstained sections of formalin-fixed paraffin-embedded tumor tissue sections or fresh tumor tissues can be provided for PD-L1, TMB, tumor infiltrating T lymphocytes, MSI-H/dMMR and EBV detection.
• The Eastern Cooperative Oncology Group Performance status (ECOG PS) 0-1
• Adequate bone marrow and organ function meets the following criteria:
• Neutrophil count (ANC)≥1.5×l09/L
• Platelet (PLT) ≥80×109/L
• Hemoglobin (Hb) level ≥9.0 g/L
• Total bilirubin level≤1.5×ULN
• Alanine aminotransferase (ALT) level≤3×ULN
• Aspartate aminotransferase (AST) level ≤3×ULN
• International normalized value (INR) or prothrombin time (PT) or activated partial thromboplastin time (aPTT) ≤1.5×ULN
• Serum creatinine (Cr) level ≤1.5×ULN
• Creatinine clearance \>50 ml/min (Calculated according to the Cockcroft-Gault formula)

You may not qualify if:

• Patients with a history of severe hypersensitivity to other monoclonal antibodies or any component of toripalimab injection (JS001).
• Preoperative pathology diagnosed as squamous cell carcinoma or neuroendocrine tumor.
• Patients have experienced or currently have other malignancies within 5 years.
• Patients have received prior therapy with anti-PD-1, anti-PD-L1 or anti-CTLA4 agent.
• Patients with history of autoimmune disease; patients with autoimmune-related hypothyroidism receive stable doses of thyroid hormone replacement therapy Eligible to participate in this study; Type 1 diabetes patients who are controlled after receiving a stable insulin treatment plan are eligible to participate in this study;
• Patients have received systemic immunostimulatory drug therapy (including but not limited to interferon or IL-2) within 4 weeks before enrollment or within 5 half-lives of the drug (whichever is shorter);
• Patients who have undergone allogeneic bone marrow transplantation or solid organ transplantation in the past;
• Active infections, including tuberculosis (clinical diagnosis includes clinical history, physical examination and imaging findings, and TB examination according to local medical routines), hepatitis B {known HBV surface antigen (HBsAg) positive, and HBV DNA ≥1000cps/ml}, hepatitis C or human immunodeficiency virus (HIV antibody positive).
• Patients with previous or cured HBV infection (defined as hepatitis B core antibody \[anti-HBc\] positive and HbsAg negative) are only eligible to participate in this study when HBV DNA is negative (HBV DNA ˂1000cps/ml).
• Patients with positive hepatitis C (HCV) antibodies are only eligible to participate in this study if the polymerase chain reaction shows negative HCV RNA.
• There is a serious neurological or mental illness, including dementia and seizures.
• Suffer from NCI-CTCAE ≥ Grade 2 peripheral neuropathy.
• Women who are pregnant or breastfeeding.
• Chronic bowel disease or short bowel syndrome.
• Those who are deficient in the enzyme dihydropyrimidine dehydrogenase (DPD).

Sponsors & Collaborators

• Wan He: lead

Study Sites (2)

Shenzhen People's Hospital

Shenzhen, Guangdong, 518020, China

RECRUITING

Shenzhen People's Hospital

Shenzhen, Guangdong, China

RECRUITING

MeSH Terms

Conditions

Stomach Neoplasms

Interventions

toripalimab

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Study Officials

• Wan He, PhD

  Shenzhen People's Hospital

  PRINCIPAL INVESTIGATOR

• Keli Zhong, PhD

  Shenzhen People's Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Wan He, PhD

CONTACT

+8618823719462; hewanshenzhen@hotmail.com

Wenwen Li, PhD

CONTACT

+8622948111; wenwenlee@live.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: August 3, 2021
• First Posted: September 2, 2021
• Study Start: September 14, 2021
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2027
• Last Updated: February 5, 2025

Record last verified: 2025-02

Locations

CN (2)